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ABSTRACT
Objective Cancer stem cells (CSCs) represent the root
of many solid cancers including pancreatic ductal
adenocarcinoma, are highly chemoresistant and
represent the cellular source for disease relapse. However
the mechanisms involved in these processes still need to
be fully elucidated. Understanding the mechanisms
implicated in chemoresistance and metastasis of
pancreatic cancer is critical to improving patient
outcomes.
Design Micro-RNA (miRNA) expression analyses were
performed to identify functionally defining epigenetic
signatures in pancreatic CSC-enriched sphere-derived
cells and gemcitabine-resistant pancreatic CSCs.
Results We found the miR-17-92 cluster to be
downregulated in chemoresistant CSCs versus non-CSCs
and demonstrate its crucial relevance for CSC biology.
In particular, overexpression of miR-17-92 reduced
CSC self-renewal capacity, in vivo tumourigenicity and
chemoresistance by targeting multiple NODAL/ACTIVIN/
TGF-β1 signalling cascade members as well as directly
inhibiting the downstream targets p21, p57 and TBX3.
Overexpression of miR-17-92 translated into increased
CSC proliferation and their eventual exhaustion via
downregulation of p21 and p57. Finally, the
translational impact of our findings could be confirmed
in preclinical models for pancreatic cancer.
Conclusions Our findings therefore identify the miR-
17-92 cluster as a functionally determining family of
miRNAs in CSCs, and highlight the putative potential of
developing modulators of this cluster to overcome drug
resistance in pancreatic CSCs.
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is the
deadliest solid cancer and currently the fourth most
frequent cause of cancer-related deaths worldwide1
and it has been predicted that by 2030 PDAC will
represent the second most frequent cause of cancer-
related death.2 Despite expanding research efforts,
there has been little substantial therapeutic progress
towards improving clinical outcome. Current ther-
apies, including the recently approved drug
Nab-paclitaxel (Abraxane),3 only slightly improve
median survival and only rarely result in long-term
progression-free survival. Therefore, comprehensive
elucidation of the mechanisms governing resistance
to treatment and rapid relapse in PDAC is urgently
needed.
In this context, cancer stem cells (CSCs) have
been identified as key players in disease progression
and resistance to conventional chemotherapies for
many carcinomas4 including PDAC.5 6 Due to their
hierarchical organisation, CSCs and non-CSCs
share the same mutational/genetic background;
however, CSCs are exclusively tumourigenic and
chemoresistant. Thus, epigenetic mechanisms likely
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Significance of this study
What is already known on this subject?
▸ Pancreatic cancer is the most lethal cancer with
limited therapeutic options.
▸ Pancreatic cancer stem cells (CSCs) are
exclusively tumourigenic and highly resistant to
chemotherapy.
▸ NODAL/ACTIVIN/TGF-β1 pathway is composed
of a core group of regulatory genes that govern
the stemness and metastatic activity of
pancreatic CSCs.
What are the new findings?
▸ miR-17-92 cluster is downregulated in
(chemoresistant) CSCs.
▸ NODAL/ACTIVIN/TGF-β1 signalling in CSCs
promotes their chemoresistance, which is
inhibited by the miR-17-92 cluster.
▸ Overexpression of miR-17-92 results in
abrogation of CSC phenotypes and eventual
loss of in vivo tumourigenicity.
How might it impact on clinical practice in
the foreseeable future?
▸ The discovery of the crucial role of the miR-17-
92/NODAL-ACTIVIN-TGF-β1/p21 Tbx3 axis in
CSCs represents an important advancement in
our understanding of CSC biology.
▸ Targeting pancreatic CSCs using miR-17-92
could be a highly specific therapeutic approach
acting upstream and downstream of the
NODAL/ACTIVIN/TGF-β1 signalling cascade.
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account for the strong phenotypical differences between these
two cell types. Indeed, several microRNAs (miRNAs) have
already been implicated in the regulation of normal stem cells as
well as CSCs,7–10 but miRs implicated in CSC chemoresistance
have remained mostly elusive to date.
MATERIALS AND METHODS
Additional details are provided in online supplementary
materials and methods
Primary human pancreatic cancer cells
Human pancreatic tumours were obtained with written informed
consent from all patients and expanded in nude mice patient-
derived xenograft (PDX).11–13 For in vitro studies, tissue frag-
ments were minced, enzymatically digested with collagenase (Stem
Cell Technologies, Vancouver, British Columbia, Canada) for
90 min at 37°C14 and after centrifugation for 5 min at 1200 rpm
the pellets were resuspended and cultured in RPMI medium
(Roswell Park Memorial Institute), 10% fetal bovine serum (FBS)
and 50 units/mL penicillin/streptomycin.
In vivo tumourigenicity and metastasis assays
For tumourigenicity assays, serial dilutions of single cells resus-
pended in Matrigel (BD Bioscience) were subcutaneously injected
into female NU-Foxn1nu nude mice (Harlan, Laboratories, UK)
and tracked for 3 months. For metastasis assays, 5×104
FACSorted mCHERRY+miR-control and miR-17-92 cells were
resuspended in 1X PBS (phosphate buffered saline) and intras-
plenically injected into NOD scid IL2 receptor γ chain knockout
(NSG) mice as previously described.15 For serial transplantation
experiments, excised tumours were digested and sorted for green
fluorescent protein (GFP) and implanted again using equal
number of cells. Mice were housed according to institutional
guidelines and all experiments were approved by the Animal
Experimental Ethics Committee of the Instituto de Salud Carlos
III (Madrid, Spain) and performed in accordance with the guide-
lines for Ethical Conduct in the Care and Use of Animals as
stated in The International Guiding Principles for Biomedical
Research involving Animals, developed by the Council for
International Organizations of Medical Sciences (CIOMS).
Drugs, recombinant proteins and inhibitors
Gemcitabine (Gemzar, Lilly SA, Alcobendas, Spain) was resus-
pended to a working concentration of 1 mg/mL in PBS.
Recombinant NODAL, ACTIVIN A and TGF-β1 were pur-
chased from R&D Systems and resuspended according to the
manufacturer’s recommendations.
In vivo treatment of established pancreatic cancers
Two mm3 pieces of low-passage xenograft tissue derived from
patients with histologically confirmed PDAC11–13 were implanted
subcutaneously into NU-Foxn1nu nude mice (Harlan), and mice
were randomised to the respective treatment groups. Size and
weight of the pancreatic tumours were monitored. Gemcitabine
was administered twice a week (125 mg/kg/mouse intraperitone-
ally). Doxycycline was administered in drinking water twice a
week at a concentration of 2 mg/mL.
More Materials and Methods can be found as online supple-
mentary information.
RESULTS
Enrichment strategy for primary chemoresistant CSCs
To identify miRNA profiles that are most representative of
human pancreatic CSCs we used two mutually complementary
approaches: First, we used anchorage-independent cultures of
primary PDAC cells (ie, spheres) to globally enrich for CSCs (see
figure 1A, B and online supplementary figure S1A).5 16 Second,
CSC-enriched sphere cultures were treated with the standard
chemotherapeutic gemcitabine to further enrich for the CSC
population via depletion of their more differentiated progenies
(see figure 1C, D and online supplementary figure S1B).
Consistently, mRNA expression of the NODAL/ACTIVIN/
TGF-β1 pathway members ALK4, TGFBRII, SMAD2, SMAD4
and TBX3, which we have previously shown to be crucial for
CSC function,16 was increased in chemoresistant CSCs (see
online supplementary figure S1C). We also noted differential
expression of cellular transporters implicated in drug resist-
ance,17 18 such as upregulation of the ABC-transporters ABCC1
and ABCG2 and downregulation of the gemcitabine-specific
transporters human concentrative nucleoside transporter and
human equilibrative nucleoside transporter (see online supple-
mentary figure S1D), both of which are mandatory for gemcita-
bine uptake.19 These data were then validated in vivo using the
original patient-derived xenografts (PDXs). PDXs were treated
with vehicle or gemcitabine (figure 1E), dissociated into single
cell suspension, and depleted for contaminating mouse stroma
cells (see online supplementary figure S1E). As predicted by our
in vitro data, CSCs were enriched following gemcitabine
treatment (figure 1F–H) and mRNA expression for members of
the NODAL/ACTIVIN/TGF-β1 pathway was also enhanced
(figure 1I).
Identification of quiescent and chemoresistant CSCs
In the CSC-enriched fraction isolated from several PDX models
we found that the cell cycle regulators p21 and p57 were con-
sistently upregulated and Cyclin D1 downregulated, as com-
pared with the more differentiated non-CSC progenies, at RNA
and protein levels (figure 2A,B). Functionally, CSCs showed a
significant reduction of cells in S phase and G2-M phase, which
was accompanied by a notable enrichment for cells in G0 and
G1 phases (figure 2C) and enhanced chemoresistance to gemci-
tabine (figure 2D). Gemcitabine-treated CSCs showed significant
enrichment for cells residing in G0 and G1, which was accom-
panied by a decrease of cells in S phase (figure 2E) and higher
mRNA levels of p21 (cyclin-dependent kinase inhibitor 1A) and
p57 (cyclin-dependent kinase inhibitor 1C) as well as downregu-
lation of cyclin-D1 (figure 2F). To further validate the presence
of a slow cycling and chemoresistant CSC subpopulation, we
stained cells with PKH2620 21 and found that only 2–3% of the
originally PKH26-labelled cells had retained strong dye labelling
after 4 weeks, indicating that those rare cells had yet to divide
(figure 2G and data not shown). Importantly, label-retaining
cells were not senescent, but rather showed enhanced sphere
formation capacity as compared with label-negative cells (see
online supplementary figure S2B) and also expressed higher
levels of the CSC surface markers (see online supplementary
figure S2A). As these cells were also highly resistant to gemcita-
bine (figure 2H) our data suggest that within the heterogeneous
population of CSCs a subpopulation of quiescent and highly
chemoresistant CSCs exists and we thus performed further
in-depth investigations to mechanistically dissect these cells.
miR-17-92 is suppressed in quiescent and chemoresistant CSCs
In order to identify epigenetic regulators of more quiescent and
thus chemoresistant CSCs, we compared miRNA expression
profiles of (1) CSC-enriched sphere-derived cells with adherent
cells and (2) Gemcitabine-treated PDXs with vehicle-treated
control tumours. Importantly, our experiments were designed to
identify miRNAs that bear relevance for CSCs across broad
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Figure 1 Enrichment strategies for cancer stem cells. (A) Representative pictures of primary pancreatic ductal adenocarcinoma (PDAC) cells
cultured as adherent monolayers or as spheres (s) (left panel). Flow cytometry analysis of CD133+CXCR4+ and CD133+SSEA1+ expression (right
panel). (B) RTqPCR analysis of pluripotency-associated genes Oct4, Sox2, Klf4 and Nanog. Data are normalised for ß-Actin expression (n=3;
*p<0.05). (C) Presence of CD133+CXCR4+ and CD133+SSEA1+ cells as assessed by flow cytometry in control and gemcitabine resistant (GR) cells
established from primary PDAC A6L and 185 cultures (D) Sphere formation capacity (n=3; *p<0.05). (E) Patient-derived xenografts were treated with
vehicle or gemcitabine (125 mg/kg/mouse biweekly; treatment from day 7 to day 28). Tumour diameters were measured using callipers, and volumes
in mm3 were calculated (n=6; *p<0.05). (F–I) Epithelial cells isolated from explanted/digested control-treated and gemcitabine resistant tumours
were analysed. (F) Flow cytometry analysis for CD133 and CXCR4 cell surface expression. (G) Sphere formation capacity. Each bar represents mean
sphere number±SD (n=3; *p<0.05). Original magnification ×100. (H) RTqPCR analysis of pluripotency-associated genes and (I) genes involved in
NODAL/ACTIVIN signalling (ALK4, NODAL, SMAD2, SMAD4, TGF-β-RII and TGF-β1) (n=3; *p<0.05).
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Figure 2 Identification of quiescent and chemoresistant cancer stem cells. (A) RTqPCR analysis of pluripotency-associated genes and genes
involved in cell cycle regulation p21, p27, p57, Cyclin-D1. Data are normalised for ß-Actin expression (n=3; *p<0.05). (B) Western blot analysis of
NANOG and cell cycle proteins p21, p27, p57 and CYCLIN-D1. Adherent (adh); sphere-derived cells (sph). (C) Cell cycle analysis using Ki67 and
DAPI staining (n=3; *p<0.05). (D) Flow cytometry analysis for apoptotic cells following 48 h of treatment with gemcitabine (100 ng/mL) as
determined with AnnexinV/DAPI staining. (E) Cell cycle analysis using Ki67 and DAPI of gemcitabine-resistant cells (n=3; *p<0.05). (F) RTqPCR
analysis of cell cycle genes p21, p27, p57 and Cyclin D1 (n=3; *p<0.05). (G) Representative images of PKH26 labelled cells after 1 day, 14 days and
28 days in culture (upper panel) and flow cytometry analysis (lower panel). (H) Percentage of PKH26+ cells before and after gemcitabine treatment
in A6L, 185 and 354 pancreatic ductal adenocarcinoma (PDAC) tumours (n=3; *p<0.05).
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populations of patients with pancreatic cancer, and as such we
used a panel of primary pancreatic tumours. Of interest, we dis-
covered a small number of miRNAs that was commonly and dif-
ferentially expressed in gemcitabine-resistant CSCs (figure 3A).
Surprisingly, most members of the miR-17-92 cluster, which are
regularly found to be upregulated in bulk cancer tissue including
pancreatic cancer,22 were also among the set of miRNAs down-
regulated in chemoresistant CSCs. To further collaborate these
findings, we next analysed the miRNA signature of
gemcitabine-resistant cells (versus vehicle-treated cells) with the
miRNA signature of CSC-enriched spheres (versus adherent
cells) and again found consistent and significant downregulation
of members of the miR-17-92 cluster together with
miR-513a-5p and miR-513b (figure 3B). Importantly, we could
confirm the downregulation of the miR-17-92 family members
by RTqPCR analysis using an independent set of primary cul-
tures (see online supplementary figure S3A) as well as
PKH26-positive (ie, quiescent) cells (see online supplementary
figure S3B). Thus, these data provide evidence that a distinct
subpopulation of slow-cycling/quiescent pancreatic CSCs exists
within the PDAC tumour bulk that is characterised by low
expression of the miR-17-92 cluster.
Loss-of-function experiments
We knocked down miR-17-92 in more differentiated cancer cells,
which regularly overexpress miR-17-92, using antisense inhibitor
of miR-17-92 (termed antagomir-17-92) in order to investigate
putative alterations in stemness features and chemoresistance.
Indeed, treatment with antagomir-17-92 resulted in increased
expression of the CSC surface marker CD133 (figure 3C),
pluripotency-associated genes and ABC transporters (figure 3D)
as well as functionally translated into enhanced self-renewal as
determined by sphere formation (figure 3E). Of note, transfected
cells showed an increase in cells residing in G0 and G1 phases
accompanied by a reduction of cells in S phase (figure 3F), a
marked increase in p21 expression (see online supplementary
figure S3C), and most importantly increased chemoresistance to
gemcitabine (figure 3G). Of note, these cells also showed
enhanced in vivo tumourigenicity as evidenced by significantly
higher tumour take rates (see online supplementary figure S3D)
and faster growth rates (data not shown). Taken together, inhib-
ition of the miR-17-92 cluster in differentiated pancreatic cancer
cells gave rise to cells reminiscent of bona fide CSCs with
enhanced chemoresistance, supporting the hypothesis that the
miR-17-92 cluster negatively controls CSC features.
Gain-of-function experiments
Adversely, overexpression of miR-17-92 in CSCs should coun-
teract CSC stemness properties. To test this hypothesis we used
a lentiviral construct expressing GFP and the common precursor
of the miR-17-92 cluster (miR-17-92) or a scrambled control
(miR-Ctrl). Compared with miR-Ctrl, miR-17-92 cluster overex-
pression led to efficient upregulation of miR-17-92 family
members in CSCs (see online supplementary figure S4A) and
subsequent downregulation of CSC surface markers (figure 4A),
pluripotency-associated genes (see online supplementary figure
S4B) and sphere formation capacity (figure 4B). Intriguingly,
miR-17-92 reduced the fraction of cells residing in G0 phase
and G1 phase while cells in S phase increased suggesting a less
quiescent phenotype (figure 4C). Indeed, we did not observe
any alterations in the level of senescence (see online supplemen-
tary figure S4C), but rather reduced quiescence, which was func-
tionally validated by PKH26 labelling (see online supplementary
figure S4D) and translated into a marked increase in
chemosensitivity to gemcitabine (see online supplementary
figure 4D) as well as Abraxane and 5-FU (see online supplemen-
tary figure S4E). These data demonstrated that miR-17-92 abro-
gated the more quiescent CSC phenotype and subsequently
restored chemosensitivity. Despite the higher proliferation rate
of miR-17-92 cells, long-term in vivo tumourigenicity was
reduced (figure 4E). During three serial in vivo passages, the
highly proliferative miR-17-92 cells gradually lost their potential
to expand and eventually exhausted as observed for more differ-
entiated cancer cells, but not for miR-Ctrl CSCs (figure 4F).
Indeed, ex vivo self-renewal capacity of miR-17-92-overexpressing
CSCs harvested after each in vivo passage significantly decreased
as observed in sphere formation assays (see online supplemen-
tary figure S4F). Moreover, cell cycle analysis validated the
initial increase in proliferation (see online supplementary figure
S4G), which eventually culminated in CSC exhaustion.
Metastatic activity represents an integrative feature of a subset
of CSCs.5 While miR-Ctrl CSCs responded robustly to key
chemoattractant factors, TGF-β1 and NODAL, miR-17-92
CSCs showed markedly reduced responsiveness in terms of
migration (see online supplementary figure S4H) and invasion
(figure 4G). As predicted by the above experiments, pharmaco-
logical inhibition of Alk4 and TGFBR2 reduced the migratory
capacity of miR-Ctrl CSCs, while the additional receptor inhib-
ition in miR-17-92 CSCs essentially ablated their entire migra-
tory capacity. Importantly, we validated these findings in vivo by
intrasplenic injection of miR-Ctrl-mCherry or miR-17-92-
mCherry CSCs to assess liver dissemination and subsequent
development of metastasis. Ten weeks postinjection, we found
significantly reduced cell dissemination in mice injected with
miR-17-92 CSCs, as determined by in situ hybridisation using a
human specific Alu II repeat probe (ALU) probe, immunohisto-
chemical analysis for human cytokeratin-19 in extracted forma-
lin-fixed paraffin embedded (FFPE) livers, and RTqPCR analysis
of mCherry and hGAPDH mRNA expression in whole liver
homogenates (figure 4H).
miR-17-92 targets NODAL/ACTIVIN/TGF-β1 signalling
To begin to understand how the miR-17-92 cluster alters the
CSC transcriptome, we used several computational methods to
search for potential targets of miR-17-92. TargetScan (http://
www.targetscan.org) identified conserved binding sites for
several members of the miR-17-92 cluster in the 30-UTR
(untranslated regioin) of the Activin-like 4 (ALK4 or ACVR1B),
TGF-β Receptor-2 (TGFBR2), SMAD2 and SMAD4 genes, a
core group of regulatory genes known to govern the stemness
and/or metastasis of pancreatic CSCs,16 p21 and p57, main reg-
ulators of quiescence23–25 and TBX3, which has been implicated
in the regulation of self-renewal of embryonic stem cells26 and
breast CSCs27 (see figure 5A and online supplementary figure
S5A). To validate these genes as direct functional targets of
miR-17-92, we analysed a panel of primary pancreatic cancer
cells expressing miR-17-92 or miR-Ctrl under the control of
doxycycline (see online supplementary figure S5B). Induction of
miR-17-92 resulted in reduced ALK4 cell surface expression
(figure 5B) as well as diminished expression of p21, p57,
pSMAD2 and Tbx3 at the mRNA (figure 5C) and protein levels
(figure 5D). We also validate the regulation of the predicted
targets by single members of the miR-17-92 cluster by qPCR
analysis following treatment with the indicated antagomirs, and
while all miR-17-92 members were capable of inhibiting the
target genes analysed, miR-92a showed a particular preference
for only one of the identified targets (p57) (see online supple-
mentary figure S5C).
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Figure 3 Inhibition of miR-17-92 promotes tumourigenicity and chemoresistance. (A) Microarray analysis represented as heat-maps, of
differentially regulated miRNAs in control (Ctrl)-treated or gemcitabine (GEM)-treated pancreatic ductal adenocarcinoma (PDAC) cells (red and green
boxes indicate upregulation and downregulation, respectively). (B) Venn diagram showing overlap between miRNAs downregulated in
gemcitabine-resistant (GR) and sphere (SPH) cultures. (C–G) Primary PDAC adherent cultures were treated with control scrambled (SCR) antagomirs
or antagomirs against the miR-17-92 cluster. (C) Flow cytometry analysis and quantification of CD133 cell surface expression (n=3; *p<0.05). (D)
RTqPCR analysis of pluripotency-associated genes. Data are normalised for ß-Actin expression (n=3; *p<0.05). (E) Sphere numbers/mL for four
primary PDAC cultures (n=3; *p<0.05). (F) Cell cycle analysis using Ki67 and DAPI (n=3; *p<0.05). (G) Chemoresistance to gemcitabine determined
with AnnexinV/DAPI staining after 48 h treatment (n=3; *p<0.05).
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Figure 4 Overexpression of miR-17-92 reverses quiescence and chemoresistance. (A–H) Cancer stem cells (CSCs) were infected with a control
lentivirus (miR-Ctrl) or a lentivirus overexpressing the pre-miR-17-92 cluster (miR-17-92) followed by comparative analyses. (A) Fold change in
surface expression of CD133 and SSEA1. Dashed line represents levels obtained in miR-Ctrl samples (n=3; *p<0.05). (B) Sphere formation capacity
(n=3; *p<0.05). (C) Cell cycle analysis using Ki67 and DAPI (n=3; *p<0.05). (D) Chemoresistance by AnnexinV/DAPI staining after treatment with
gemcitabine (n=3; *p<0.05). (E) In vivo tumourigenicity results. CSC frequencies (Freq) determined using the extreme limiting dilution analysis
algorithm (http://bioinf.wehi.edu.au/software/elda/index.html) (*p<0.05). (F) In vivo serial transplantation results. Tumour volumes (mm3) were
determined at indicated times. At 5 weeks postimplantation, tumours were explanted and serially transplanted into naïve nude mice (n=4;
*p<0.05). (G) Representative images of invaded cells (upper panel). Percentage of cells that transmigrated through Matrigel following stimulation
with NODAL, ACTIVIN or TGF-ß1 (lower panel; n=3; *p<0.05). (H) RTqPCR quantification of mCHERRY mRNA copies/μg of total RNA in fresh liver
homogenates from NSG mice 10 weeks after intrasplenic injection of 5×104 miR-Ctrl or miR-17-92 mCherry-labelled cells (left panel; n=4; *p<0.05))
and in situ hybridisation for ALU probe and immunohistochemistry for CK-19 in explanted FFPE livers (right panel).
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Figure 5 miR-17-92 targets NODAL/ACTIVIN/TGF-β signalling. (A) Graphic representation of predicted targets of the miR-17-92 cluster. (B) Flow
cytometry analysis for ALK4 cell surface expression before and 96 h after treatment with doxycycline 2μg/ml. (C) RTqPCR analysis of miR-17-92 target
genes after 72 h of treatment with doxycycline. Data are normalised for ß-Actin expression (n=3; *p<0.05). (D) Western blot analysis of cell cycle
proteins p21 and p57, pSMAD2 and TBX3. (E) The complete 30 UTR of ALK4 and TBX3 genes were cloned into the GLuc Dual-luciferase reporter vector
and cotransfected with miR-17-92 or miR-Ctrl mimics (n=3; *p<0.05). Luciferase activity was measured and normalised to Renilla luciferase activity
(n=4; * p<0.05). (F) Luciferase activity of pCAGA12-luc SMAD4 reporter after stimulation with NODAL, ACTIVIN and TGF-β1 in cells overexpressing
miR-17-92 versus control cells. (G) RTqPCR analysis of p21 and TBX3 mRNA expression (upper panel) and western blot analysis for pSMAD2, p21 and
GAPDH (lower panel) after stimulation with TGF-β1, NODAL and ACTIVIN in cells overexpressing miR-17-92 versus control cells.
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To further show a direct interaction between miR-17-92
members and their targets, we assessed the ability of the cluster
members to interact with the 30 UTR of Alk4 and Tbx3 using
luciferase reporter constructs. The complete 30 UTR of the Alk4
or Tbx3 gene were cloned into the GLuc Dual-luciferase
reporter vector and CSCs were cotransfected with GLuc vectors
containing the 30 UTR of Alk4 or Tbx3 and miR-17-92 mimics.
As expected, we found significantly lower luciferase expression
in miR-17-92 CSCs (figure 5E). To functionally validate
SMAD4 as a direct target of miR-17-92, we also used a
pCAGA12-luciferase SMAD4 reporter. After stimulation with
TGF-β1, NODAL or ACTIVIN, we observed an increase in luci-
ferase expression in miR-Ctrl cells, while in cells overexpressing
miR-17-92 the effect was significantly diminished, indicating
that SMAD4 is strongly inhibited by miR-17-92 (figure 5F) and
suggesting that elevated miR-17-92 levels in bulk PDAC tumour
cells could contribute to loss of SMAD4 expression in bulk
PDAC samples.28 As it has been reported that TGF-β1-mediated
cancer cell migration and invasion is dependent on p21,29 we
stimulated cells with TGF-β1, NODAL or ACTIVIN to evaluate
the induction of p21, Tbx3 and pSMAD2. In control cells, we
observed increased expression of p21, TBX3 and pSMAD2,
while in cells overexpressing miR-17-92, this effect was abro-
gated (figure 5G).
Knockdown of p21 inhibits CSC phenotypes including
chemoresistance
The results presented above suggested that the targets of the
miR-17-92 cluster are essential for CSCs. While we have shown
previously that the miR-17-92 target Alk4 is crucial for self-
renewal of CSCs, we therefore focused on p21 as it was specific-
ally downregulated in chemoresistant CSCs (figure 2A). Knock
down of p21 using short-hairpin RNAs (sh-p21) (figure 6A)
resulted in reduced sphere formation capacity during serial pas-
saging (figure 6B), even though sh-p21 cells showed increased
overall proliferation as determined by cell cycle analysis
(figure 6C). As these in vitro data suggest an important role for
p21 in CSCs biology, we next validated our findings in vivo.
Limiting dilution assays using sh-scramble and sh-p21 CSCs
revealed significantly reduced in vivo tumourigenicity, particu-
larly when low numbers of cells were injected (figure 6D).
Moreover, sh-p21 cells lost their invasive capacity (see online
supplementary figure S6A) and became chemoresistant to gemci-
tabine (figure 6E). Thus, by merely silencing p21, one of the
many targets of the miR-17-92 cluster, we were able to mimic,
at least partially, the phenotypes of miR-17-92 CSCs.
Knockdown of TBX3 inhibits CSC phenotypes
Next, we studied the role of TBX3 in CSCs based on its essen-
tial role in embryogenesis and stem cell function30 as well as its
implication in oncogenic processes.31–33 Indeed, TBX3 was con-
sistently upregulated in sphere-derived CSCs at the mRNA (see
online supplementary figure S6B) and protein levels (figure 6F,
left panel). Consistently, TBX3 was significantly increased in
CSCs defined as CD133+ (see online supplementary figure
S6C) or ALK4+ (see online supplementary figure S6D), and
subsequent TBX3 knockdown (figure 6F, right panel) resulted
in a significant reduction of CSC surface markers (figure 6G)
and impaired sphere formation capacity (figure 6H). Very
recently, TBX3 was identified as a TGF-β1 target with a dual
function: inhibition of proliferation and promotion of the
migration of breast epithelial cells.34 Indeed, silencing of TBX3
in CSCs also abrogated their invasive capacity, specifically when
stimulated with NODAL, ACTIVIN or TGF-β1 (see online
supplementary figure S6E). Thus, like p21, TBX3 also repre-
sents a crucial factor through which the miR-17-92 cluster nega-
tively regulates CSC phenotypes.
Targeting quiescent CSCs as a novel therapeutic approach
for PDAC
Finally, we aimed to provide proof of concept for the transla-
tional relevance of our findings and performed in vivo thera-
peutic intervention studies by induced overexpression of
miR-17-92 in established PDAC models using a doxycycline-
switchable system. Once tumours had formed (∼100 mm3),
doxycycline was administered to induce miR-17-92 expression.
Some mice also received gemcitabine (biweekly 125 mg/kg intra-
peritoneally) from day 14 to day 63, to mimic standard of care.
No significant differences were observed between miR-Ctrl and
miR-17-92 tumours with respect to bulk tumour growth, which
was expected based on the extensive proliferative capacity of
bulk tumour cells. Intriguingly, however, miR-17-92 tumours
were significantly more sensitive to gemcitabine (see figure 7A
and online supplementary figure S7A) or Abraxane (see online
supplementary figure S7B). Weight assessment (figure 7B) and
flow cytometry analysis revealed a significant decrease in CSC
content for miR-17-92 tumours treated with gemcitabine
(figure 7C). Consistently, limiting dilution tumourigenicity assays
showed reduced in vivo tumourigenicity for cells overexpressing
miR-17-92 alone and additionally treated with gemcitabine, indi-
cating that high levels of miR17-92 forced CSCs into a more dif-
ferentiated and proliferative state, reducing their self-renewal
capacity in vivo and at the same time sensitising them to gemcita-
bine (figure 7D).
CONCLUSION/DISCUSSION
Pancreatic cancers contain a rare population of undifferentiated
‘stem-like’ cells that are highly tumourigenic and give rise to
more differentiated progenies.5 6 Mechanistically, these cells
have activated pathways distinct from their non-differentiated
counterparts, including activated NODAL/ACTIVIN signalling,
which we have previously identified as an essential regulator of
CSC ‘stemness’.16 As CSCs and their more differentiated pro-
genies share the same genetic background, we hypothesised that
the apparent mechanistic differences that exist between CSCs
and non-CSCs are related to a unique epigenetic signature. As
such, we aimed to better characterise the epigenetic regulatory
machinery of pancreatic CSCs using complementary approaches.
Intriguingly, we were able to identify a specific and common
miRNA signature present in treatment-naïve CSCs and
gemcitabine-resistant CSCs isolated from a representative set
of PDXs.
Specifically, we found the miR-17-92 cluster, composed of six
members miR-17, miR-18a, miR-19a, miR-19b, miR-20a and
miR-92a, to be markedly suppressed in pancreatic CSCs as com-
pared with their more differentiated and chemosensitive coun-
terparts. Interestingly, the miR-17-92 cluster has been validated
as an oncogenic regulator and at the same time as a tumour sup-
pressive regulator. This dual role can be explained, in part, by
the spectrum and diversity of the mRNAs targeted by this
cluster and the tumour and/or cellular context. While
miR-17-92 has been shown to serve as an oncogene in some
human cancers,35 36 loss of heterozygosity at 13q12-q13 has
also been linked to accelerated tumour progression and poor
outcome in breast cancer, squamous cell carcinoma of the
larynx, retinoblastoma, hepatocellular carcinoma and nasopha-
ryngeal carcinoma,37 38 and deletion of the miR-17-92 cluster
has been observed in a subset of patients with ovarian cancer,
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Figure 6 Knockdown of p21 or TBX3 inhibits cancer stem cell (CSC) phenotypes. (A–H) CSCs were stably infected with lentiviruses expressing a
scrambled control shRNA (Ctrl), an shRNA against p21 (sh-p21) or an shRNA against TBX3 (sh-TBX3). (A) Western blot analysis of p21 in infected
cells. ADU, arbitrary densitometric unit. (B) Serial sphere formation capacity of sh-p21-infected pancreatic ductal adenocarcinoma (PDAC) cells (n=3;
*p<0.05). (C) Cell cycle analysis using Ki67 staining (n=3; *p<0.05). (D) Limiting dilution tumourigenicity analysis of sh-p21-infected 185 cells.
Freq=CSC frequency (*p<0.05). (E) Chemoresistance to gemcitabine as determined with AnnexinV/DAPI staining after 7 days treatment (n=3;
*p<0.05). (F) Comparative western blot analysis of TBX3 protein levels in adherent (Adh) and sphere (Sph) from several primary PDAC cultures and
densitometric quantification (left panel). Western blot analysis for TBX3 in cells expressing sh-Tbx3 (sh1 and sh2) and densitometric quantification
(right panel). (G) Flow cytometry analysis for CSC surface markers CD133 and CXCR4 (n=3; *p<0.05). (H) Sphere formation capacity of
sh-TBX3-infected PDAC cells (n=3; *p<0.05).
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breast cancer and melanoma.39 Moreover, the role of the
miR-17-92 cluster as a tumour suppressor has been demon-
strated in breast cancer cells,40 in GI stromal tumours41 and in
oral squamous carcinoma.42 Thus, the duality of this cluster
reflects the complexities of cancer progression as well as the
intricacies of the regulation network of miRNAs and their
targets in a tumour and cell type-dependent manner.
Our data now demonstrate that targeted inhibition of
miR-17-92 in pancreatic non-CSCs equipped these cells with
features that are inherently restricted to bona fide CSCs, such as
upregulation of CD133, increased sphere formation capacity,
reduced proliferation and subsequent in vitro chemoresistance,
and more importantly, increased in vivo tumourigenicity and in
vivo resistance to chemotherapy. In contrast, overexpression of
miR-17-92 in CSCs resulted in loss of stem-like features, includ-
ing reduced self-renewal (ie, sphere formation capacity), and
decreased expression of CSC surface markers, but also increased
proliferation. The latter was most intriguing as it resulted in
exhaustion of normally slow-cycling CSCs, which was reflected
in decreased in vivo tumourigenicity during serial passaging and
increased sensitivity to gemcitabine and Abraxane, respectively.
Thus, our data demonstrate that suppression of miR-17-92 is
crucial for maintaining the stemness phenotype in CSCs, while
the apparent overexpression in non-CSCs equips these cells with
extensive, albeit not indefinite, proliferative capacity.
Several members of the miR-17-92 cluster have been shown
to target diverse pathways, including TGF-β143 44 and HIF-1α
signalling,45 but their role in the regulation of pancreatic cancer
and specifically of pancreatic CSCs remained to be determined.
Intriguingly, we were able to identify several targets clustering
around pathways that have been previously associated with
CSCs regulation and ‘stemness’ (eg, NODAL/ACTIVIN pathway
and cell cycle regulators). We found miR-18a to regulate
SMAD2 and SMAD4, two key components of the NODAL/
ACTIVIN signalling cascade. miR-17 and miR-20a targeted a
wider range of genes including TGFBR2, ALK4, SMAD4, as
well p21 and TBX3, all of which are again linked to NODAL/
ACTIVIN/TGF-β signaling16 44 and cell cycle regulation.24 29
Finally, miR-92a was found to also target TBX3 as well as p57.
The sum of these data therefore suggests that miR-17-92 specif-
ically dampens NODAL/ACTIVIN signalling in a multifaceted
way by acting upstream and downstream of pSMAD2/SMAD4.
As the biological relevance of targeting NODAL/ACTIVIN
and ALK4 in CSCs has already been demonstrated by our
laboratory,16 herein we focused our efforts on the other less
characteristic miR-17-92 targets p21 and TBX3. For p21, we
Figure 7 Targeting quiescent cancer stem cells (CSCs) as a novel therapeutic approach for pancreatic ductal adenocarcinoma (PDAC).
(A) Experimental set-up for in vivo treatment (upper panel) and treatment effects of gemcitabine (GEM) in 185 patient-derived xenograft (PDX)
tumours with or without induction of miR-17-92 expression (lower panel). The mean tumour volumes are reported (n=6 tumours per group;
*p<0.05). (B) Representative picture (upper panel) and quantification of tumour weight (lower panel; n=6; *p<0.05).). (C) Flow cytometry analysis
of CSC markers CD133, CXCR4 and SSEA1 in cells isolated from resected tumours on d 84 (n=4; *p<0.05). (D) Limiting dilution tumourigenicity
analysis of PDAC cells isolated from d 84 tumours (*p<0.05).
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observed that this cell cycle regulator was overexpressed in che-
moresistant CSCs suggesting an important role for p21 in con-
trolling CSC proliferation. Indeed, there is strong evidence from
murine models of normal haematopoietic and leukaemic stem
cells that p21 is an important regulator of self-renewal. In the
absence of p21, normal haematopoietic stem cells as well as
transformed leukaemic stem cells functionally exhaust over
time.25 46 Our data now also support a role for p21 in the pre-
vention of pancreatic CSC exhaustion through cell cycle restric-
tion. Inhibiting p21 in CSCs resulted in impaired self-renewal
and chemoresistance. the accumulation of DNA damage as evi-
denced by increased gH2AX foci and their subsequent elimin-
ation/dysfunction likely via mitotic chaos.
TBX3 is a transcription factor that belongs to the T-box gene
family and contains a conserved DNA-binding domain called
the T-box.47 TBX3 plays an important role in embryonic devel-
opment, cell cycle regulation and cancer progression.27 33 For
example, overexpressing TBX3 in non-tumourigenic early stage
melanoma cells promoted tumour formation and invasion.
Furthermore, it has been shown that TBX3 functions as a recip-
rocal switch between substrate-dependent cell proliferation and
tumour invasion.33 TBX3 also plays a pivotal role in
TGF-β1-mediated antiproliferation and promigration34 and in
the regulation of NODAL signalling in embryonic stem cells.48
Here we now show that TBX3 is upregulated in CSCs and its
knockdown negatively affects CSC phenotypes via TGF-β1-
dependent and NODAL-dependent mechanisms. Thus, our data
demonstrate the importance of TBX3 in the regulation of pan-
creatic CSCs self-renewal and metastasis via regulation of
TGF-β1 and NODAL signalling.
In summary, our study has identified the miR-17-92 cluster as
a previously unknown negative master regulator of pancreatic
CSCs. While we are still investigating why this cluster is differ-
entially expressed in CSCs versus non-CSCs, we have observed
that MYC, a known regulator of the miR-17-92 cluster,36 38 43
is consistently downregulated in pancreatic CSCs. More import-
antly, we demonstrate, for the first time, that the miR-17-92
cluster regulates CSCs via targeting ALK4, p21 and TBX3.
Overexpression of miR-17-92 led to abrogation of CSC pheno-
types and eventual loss of in vivo tumourigenicity, whereas sup-
pression of miR-17-92 contributed to PDAC aggressiveness
including invasiveness. In addition, it is important to note that
the simultaneous targeting of the different components of the
NODAL/ACTIVIN signalling cascade as well as its downstream
effectors through multiple miRNAs of the miR-17-92 cluster
allows for a very tight control of this transcriptional programme.
Thus, from a clinical point of view, targeting pancreatic CSCs
using the multifaceted effects of miR-17-92 on NODAL/
ACTIVIN signalling could be a promising and highly specific
therapeutic approach, as it would result in reduced expression
of ALK4, and induce direct miR-17-92-mediated repression of
NODAL/ACTIVIN responsive genes. The latter would avoid the
bias of the SMAD4 status as Smad4 is mutated in about 50% of
pancreatic tumours,49 even though these tumours still maintain
active NODAL/ACTIVIN signalling as a key regulator of their
self-renewal capacity.16 Indeed, the plasmid-based production of
modified miRNA, which also allows for the generation of poly-
cistronic constructs such as miR-17-92,50 could represent an
important next step to further evaluate this novel therapeutic
concept in preclinical models of PDAC.
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Erratum: The miR-17-92 cluster counteracts
quiescence and chemoresistance in a
distinct subpopulation of pancreatic cancer
stem cells
Cioffi M, Trabulo SM, Sanchez-Ripoll Y, et al. The miR-17-92 cluster counteracts quiescence
and chemoresistance in a distinct subpopulation of pancreatic cancer stem cells. Gut
2015;64:1936-48. Two errors have been corrected in the text. In the paragraph “Knockdown
of p21 inhibits CSC phenotypes including chemoresistance”, line 5 has been corrected to “…
we therefore focused on p21 as it was specifically upregulated in chemoresistant CSCs (figure
2A)”. In the same paragraph, line 16 has been corrected to “and became chemosensitive to
gemcitabine (figure 6E)”.
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